Structural insights into frog skin-derived cyclic peptides as selective matriptase inhibitors
European Journal of Medicinal Chemistry · 2026
DOI: 10.1016/j.ejmech.2025.118331 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Medicinal Chemistry, 2026. Verfasst von Agata Gitlin-Domagalska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biochemistry, University of Gdańsk, 80-309, Gdańsk, Poland. Hauptthemen laut MEDLINE: Skin, Peptides, Cyclic, Serine Endopeptidases, Serine Proteinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Narodowe Centrum Nauki, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Matriptase is a type II transmembrane serine protease implicated in epithelial integrity and cancer progression, making it a promising therapeutic target. However, the development of highly selective matriptase inhibitors remains a major challenge due to its structural homologies and similar proteolytic specificities with related proteases such as TMPRSS6. In this study, we investigated a series of cyclic peptides derived from the frog-skin Bowman-Birk inhibitor HV-BBI, focusing on their inhibitory activity and selectivity toward matriptase. Among them, compound 6, a 13-residue monocyclic peptide with a C-terminal amide, emerged as a standout candidate, demonstrating nanomolar potency and remarkable 1000-fold selectivity over TMPRSS6. Unexpectedly, when the C-terminal amide was replaced with a carboxylate group, the compound exhibited a significant loss of potency against matriptase. Moreover, structure-activity relationship studies, including alanine scanning and C-terminal residue substitutions, revealed that residues Lys5, Ser6, Ile7, and Arg10 are critical for matriptase binding, while the C-terminal Phe13 is less essential. Molecular dynamics simulations highlighted key inter- and intramolecular interactions that stabilize the peptide-enzyme complex and explain the superior potency of compound 6 compared to its analogues. Importantly, compound 6 retained its inhibitory activity in a cellular model without inducing cytotoxicity. These findings establish HV-BBI-derived peptides as promising scaffolds for the development of highly selective matriptase inhibitors and provide valuable structural insights for future therapeutic design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biochemistry, University of Gdańsk, 80-309, Gdańsk, Poland.
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
- Department of Molecular Biochemistry, University of Gdańsk, 80-309, Gdańsk, Poland. Electronic address: dawid.debowski@ug.edu.pl.
Förderung
- Narodowe Centrum Nauki
- Canadian Institutes of Health Research
Zitieren
APA
Gitlin-Domagalska, A., Hassanzadeh, M., Helbik-Maciejewska, A., Lepage, M., Joushomme, A., Désilets, A., Dębowski, D., Boudreault, P. L., Leduc, R., & Rolka, K. (2026). Structural insights into frog skin-derived cyclic peptides as selective matriptase inhibitors. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2025.118331
Vancouver
Gitlin-Domagalska A, Hassanzadeh M, Helbik-Maciejewska A, Lepage M, Joushomme A, Désilets A, et al. Structural insights into frog skin-derived cyclic peptides as selective matriptase inhibitors. European Journal of Medicinal Chemistry. 2026. doi:10.1016/j.ejmech.2025.118331
BibTeX
@article{GitlinDomagalska2026,
author = {Gitlin-Domagalska, Agata and Hassanzadeh, Malihe and Helbik-Maciejewska, Aleksandra and Lepage, Matthieu and Joushomme, Alexandre and Désilets, Antoine and Dębowski, Dawid and Boudreault, Pierre-Luc and Leduc, Richard and Rolka, Krzysztof},
title = {Structural insights into frog skin-derived cyclic peptides as selective matriptase inhibitors},
journal = {European Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1016/j.ejmech.2025.118331}
}
EUVIMED